Logo

NovoCodex Collaborates with Ambrx to Develop and Commercialize its ARX305 in China

Share this

NovoCodex Collaborates with Ambrx to Develop and Commercialize its ARX305 in China

Shots:

  • Ambrx to receive up front- development milestones and royalties on sales of ARX305 in China and retain rights to develop & commercialize ARX305 outside China. NovoCodex to get right to develop & commercialize ARX305 in China- will fund global activities to the end of P-I and is eligible to share ARX305 sales outside China
  • Earlier- the companies collaborated to develop & commercialize ARX788- which is currently in P-I study for HER2 positive breast and gastric cancers
  • ARX305 is an anti-CD70 ADC- expected to deliver direct killing to CD70-overexpressing tumor and improvement of the immune suppression in the tumor microenvironment with its anticipated onset of P-I study in H1’21  

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Xconomy


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions